Penumbra (NYSE:PEN) Director Thomas Wilder Sells 186 Shares

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total value of $47,230.98. Following the completion of the transaction, the director directly owned 186 shares in the company, valued at $47,230.98. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Thomas Wilder also recently made the following trade(s):

• On Tuesday, August 12th, Thomas Wilder sold 372 shares of Penumbra stock. The shares were sold at an average price of $240.16, for a total value of $89,339.52.

Penumbra Stock Up 1.0%

Shares of NYSE PEN opened at $256.05 on Friday. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52 week low of $190.08 and a 52 week high of $310.00. The firm’s fifty day moving average is $257.64 and its 200 day moving average is $262.85. The company has a market cap of $9.99 billion, a price-to-earnings ratio of 68.10, a PEG ratio of 2.31 and a beta of 0.41.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.05. The business had revenue of $339.46 million during the quarter, compared to analysts’ expectations of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The firm’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.64 EPS. Penumbra has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Citigroup cut their target price on Penumbra from $320.00 to $285.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 9th. Morgan Stanley lifted their price objective on Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Evercore ISI began coverage on Penumbra in a research note on Tuesday, September 2nd. They set an “outperform” rating and a $300.00 target price on the stock. Truist Financial set a $310.00 price target on Penumbra and gave the stock a “buy” rating in a research note on Wednesday, July 30th. Finally, Wall Street Zen cut shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $302.93.

Institutional Investors Weigh In On Penumbra

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PEN. Invesco Ltd. lifted its position in Penumbra by 1,139.3% during the second quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after buying an additional 582,369 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Penumbra by 437.0% in the 1st quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock worth $188,159,000 after acquiring an additional 572,606 shares in the last quarter. Norges Bank bought a new position in shares of Penumbra in the 2nd quarter worth about $114,014,000. Lord Abbett & CO. LLC purchased a new position in Penumbra during the 1st quarter valued at about $63,731,000. Finally, Qube Research & Technologies Ltd bought a new stake in Penumbra during the second quarter worth about $53,818,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.